Biologics are the drugs generated from natural sources including human, animal, or microbial cells and consist of carbohydrates, proteins, or nucleic acids. Moreover, biologics include human cells and tissues, live attenuated microbes, allergenic extracts, cell and gene treatments. Biologics medicines are available for the treatment of disease such as chronic disease, cardiovascular disease, and so on. 

Pharmaceutical companies had to outsource different stages of the biologic development and manufacturing process to highly effective service provider organizations due to the fast-paced nature of the biologic industry and the insufficient or absence of internal biologic development and manufacturing capabilities and capacities of biopharmaceutical companies. Major pharmaceutical corporations outsource the production of biologics to contract research organizations, contract manufacturing organizations, and others in order to concentrate on their core competencies while reducing operational costs.

Market Dynamics

Key market players are focused on inorganic strategies such as agreements to strengthen its product portfolio, is expected to drive the growth of global biologics outsourcing market over the forecast period. For instance, in November 2021, GenScript ProBio, a subsidiary of GenScript Biotech Corporation offering end-to-end CDMO services, announced that the company had entered into an agreement for cell line development, drug substance, and drug product manufacturing of therapeutic and diagnostic monoclonal antibodies (mAbs).

Key market players is focused on facility expansion to strengthen the company’s service and product portfolio, is expected to propel the growth of global biologics outsourcing market over the forecast period. For instance, in December 2022, Catalent, Inc. a pharmaceutical company, announced that it is establishing a new biologics analytical center of excellence in Durham, England, within North Carolina’s Research Triangle, to offer comprehensive standalone analytical development and testing for biologic drug modalities, including cell and gene therapies. The company planned to invest up to US$ 40 million to fit the 80,000 square-foot facility with equipment and instrumentation, including automation and digitization capabilities

Key features of the study:

• This report provides in-depth analysis of the global biologics outsourcing market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global biologics outsourcing market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies. Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Abzena Ltd. Fujifilm Diosynth Biotechnologies, KBI Biopharma, EirGenix, Inc., Curia Global, Inc., Bionova Scientific, Inc., Boehringer Ingelheim International GmbH., STC Biologics., Abbvie Inc., Avid Bioservices, Inc., Catalent Inc., Emergent, Eurofins Scientific, Genentech, Inc., Genscript Biotech Corporation, JSR Corporation, Lonza, Merck KGaA, Rentschler Biopharma SE.        
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global biologics outsourcing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biologics outsourcing market

Detailed Segmentation:

• Global Biologics Outsourcing Market, By Product and Service Type:
  • Product
    • Antibodies
    • Recombinant Proteins
    • Vaccines
    • Others
  • Services
    • Cell Development
    • Process Development
    • Analytical Testing
    • cGMP Manufacturing
    • Others
• Global Biologics Outsourcing Market, By Source:
  • Mammalian
  • Microbial
• Global Biologics Outsourcing Market By Application:
  • Oncology
  • Cellular and Gene Therapy
  • Blood & Blood-Related Products Development
  • Vaccine Development
  • Stem Cell Research
  • Others
• Global Biologics Outsourcing Market By End User:
  • Pharmaceutical Industries
  • Biotechnology Industries
  • CDMO
• Global Biologics Outsourcing Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Thermo Fisher Scientific Inc.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Abzena Ltd.
  • Fujifilm Diosynth Biotechnologies
  • KBI Biopharma,
  • EirGenix, Inc.
  • Curia Global, Inc.
  • Bionova Scientific, Inc.
  • Boehringer Ingelheim International GmbH.
  • STC Biologics.
  • Abbvie Inc.
  • Avid Bioservices, Inc.
  • Catalent Inc.
  • Emergent
  • Eurofins Scientific
  • Genentech, Inc.
  • Genscript Biotech Corporation
  • JSR Corporation
  • Lonza
  • Merck KGaA
  • Rentschler Biopharma SE.

“*” marked represents similar segmentation in other categories in the respective section.